Suicide in Old Age: A Tragedy of Neglect

1996 ◽  
Vol 41 (4) ◽  
pp. 217-222 ◽  
Author(s):  
Geoffrey Duckworth ◽  
Hazel McBride

Objective: To investigate the incidence and treatment of depression in geriatric suicide. Method: All coroners' records, autopsy and police reports for suicide victims aged 65+ in Ontario (n = 543) over 3 years were examined. Results: Over 80% of the elderly who committed suicide received no psychiatric referral. Of the sample, 87% were untreated while only 13% received antidepressants. Tricyclics, which are lethal in overdose, were the drugs of choice. None of the sample was treated with the safer specific serotonin reuptake inhibitors (SSRIs). Females were 3 times as likely to be treated as were males, and those seeing psychiatrists were 4 times more likely to be treated with antidepressants than those seeing general practitioners (GPs). The physically ill were rarely treated. Conclusions: These findings suggest that early geropsychiatric assessment and vigorous treatment could prevent many suicides in old age.

1995 ◽  
Vol 40 (5) ◽  
pp. 147-148 ◽  
Author(s):  
I.C. Taylor ◽  
J.G. McConnell

Depression in the elderly is a common problem, cited as occurring in up to 10% of elderly people living at home, half of whom may need specialist referral.1 The introduction of selective serotonin reuptake inhibitors has been reported as a major advance in the treatment of depression in that they are less sedating, have fewer anticholinergic effects and are less toxic in overdose.2 We report three cases of severe hyponatraemia, seen in the past 12 months, associated with the selective serotonin reuptake inhibitors fluoxetine and sertraline. Hyponatraemia has been reported as a rare adverse effect of selective serotonin reuptake inhibitors.3,4


2000 ◽  
Vol 10 (4) ◽  
pp. 349-373 ◽  
Author(s):  
Richard Marc Patel

IntroductionWith their ease of administration, relatively benign side-effect profile and safety in overdose, in the United States the selective serotonin reuptake inhibitors (SSRIs) have become de facto first choice in the treatment of geriatric depression, displacing tricyclic antidepressants (TCAs). In this paper, the relevant literature regarding neurochemistry, kinetics, dosing, efficacy and differential side-effect profiles of citalopram, fluvoxamine, fluoxetine, sertraline, and paroxetine, the five currently available SSRIs in the USA, will be reviewed with special emphasis on geriatric data. Of late, considerable controversy has been generated regarding whether SSRIs are as effective as TCAs in severe and melancholic depressive subtypes. This important issue will be explored and the relative utility of all the SSRIs in the elderly patient compared and contrasted. Finally, reasons for difficulties in comparing results across studies will be elucidated.


Drugs ◽  
2006 ◽  
Vol 66 (16) ◽  
pp. 2095-2107 ◽  
Author(s):  
Joost P van Melle ◽  
Peter de Jonge ◽  
Maarten P van den Berg ◽  
Harm J Pot ◽  
Dirk J van Veldhuisen

Sign in / Sign up

Export Citation Format

Share Document